| Website | tvm-capital.com |
| @tvmcapital | |
| Phone | +49 (89) 998 992-0 |
| Employees | |
| Founded | 1983 |
TVM Capital is a global venture and growth capital firm with a 25 year operating track record. From their headquarters in Munich, and their offices in Boston and most recently also New York, they have financed more than 240 emerging companies in technology and the life sciences. During the last 15 years they have become increasingly specialized in these two attractive high-growth sectors. Their key objective as investors is to enhance company growth by harnessing the power to innovate at all levels – technological, strategic, marketing and geographical - incorporating effective international management and securing adequate financial backing.
| Company | Date | Round | Size | Participants |
| Kaneq Bioscience | 1/13 | Venture Round | 1 | |
| Definiens | 10/12 | Venture Round | €10M | 2 |
| bluebird bio | 7/12 | Series D | $60M | 7 |
| Argos Therapeutics | 4/12 | Series D | $25M | 5 |
| Probiodrug | 1/12 | Venture Round | €15M | 6 |
| bluebird bio | 4/11 | Venture Round | $30M | 5 |
| f-star Biotech | 4/11 | Venture Round | €15M | 7 |
| Cambridge Broadband Networks | 12/10 | Venture Round | $16.5M | 5 |
| Anchor Therapeutics | 8/10 | Series B | $10M | 3 |
| Cerenis Therapeutics | 7/10 | Series C | €40M | 7 |
| DIREVO Industrial Biotechnology | 4/10 | Series D | $8.1M | 2 |
| VPIsystems | 3/10 | Venture Round | $4M | 5 |
| bluebird bio | 3/10 | Series B | $35M | 5 |
| DIREVO Industrial Biotechnology | 2/10 | Venture Round | €6M | 2 |
| Probiodrug | 11/09 | Series B | $54M | 8 |
| Ubidyne | 8/09 | Series B | $43M | 4 |
| Rapid Micro Biosystems | 8/09 | Series A | $18.6M | 4 |
| Proteon Therapeutics | 5/09 | Series B | $50M | 8 |
| Cambridge Broadband Networks | 2/09 | Venture Round | $7.5M | 4 |
| Extend Media | 12/08 | Series C | $10M | 3 |
| Silicon Hive | 10/08 | Venture Round | $7M | 3 |
| CommProve | 9/08 | Venture Round | $14M | 3 |
| SpePharm | 8/08 | Venture Round | €26M | 3 |
| BitWave | 8/08 | Series B | $10.2M | 3 |
| Arteris | 5/08 | Series C | $7.5M | 5 |
| Winbox Technologies | 5/08 | Series A | $1.56M | 1 |
| Concert Pharmaceuticals | 4/08 | Series C | $37M | 12 |
| CoreOptics | 4/08 | Venture Round | $25M | 8 |
| Albireo | 2/08 | Series A | $40M | 2 |
| Vivendy Therapeutics | 1/08 | Venture Round | $30.5M | 2 |
| Ascent Therapeutics | 11/07 | Series A | $8M | 3 |
| DIREVO Industrial Biotechnology | 10/07 | Series C | $16.8M | 7 |
| Proteon Therapeutics | 9/07 | Series A | $12M | 4 |
| Arteris | 6/07 | Series B | $8.1M | 4 |
| Netviewer | 5/07 | Venture Round | $12.2M | 2 |
| Silicon Hive | 4/07 | Series A | $10M | 3 |
| Extend Media | 4/07 | Series B | $12M | 3 |
| Hymite | 1/07 | Series B | $11.5M | 4 |
| Concert Pharmaceuticals | 11/06 | Series B | $48.5M | 8 |
| RenaMed Biologics | 9/06 | Venture Round | $40M | 9 |
| Concert Pharmaceuticals | 7/06 | Series A | $10M | 5 |
| CoreOptics | 7/06 | Venture Round | $28M | 6 |
| Cambridge Broadband Networks | 1/06 | Series D | $9M | 3 |
| Impress Software Solutions | 9/05 | Series C | $10M | 5 |
| Ubidyne | 9/05 | Series A | $15.5M | 2 |
| Amnis | 8/05 | Series C | $11.3M | 4 |
| Sirtris Pharmaceuticals | 3/05 | Series B | $27M | 6 |
| VPIsystems | 3/05 | Series C | $9M | 7 |
| Aventeon | 2/05 | Series B | $5M | 3 |
| Sirtris Pharmaceuticals | 12/04 | Series A | $13M | 5 |
| BitWave | 1/04 | Series A | $13M | 3 |
